Erythropoietin controls heme metabolic enzymes in normal human bone marrow culture.
Erythropoietin (Epo) was found to act as a concentration-dependent inducer of aminolevulinic acid (ALA) synthase and porphobilinogen (PBG) deaminase in normal human bone marrow in culture. Epo increased enzymatic activities in individual plated nucleated cells. At a low concentration of Epo, heme oxygenase activity did not change in human bone marrow erythroid progenitor cells. However, Epo at a concentration of 2 U/ml increased heme oxygenase as demonstrated by an increase in both the enzyme protein and its mRNA. In experiments with an inhibitor of heme synthesis, succinylacetone (SA), Epo failed to stimulate erythroid colony-forming unit (CFU-E) growth, but this CFU-E inhibition by SA was completely overcome by the addition of hemin. Epo nevertheless potentiated induction of ALA synthase in the presence of SA. Hemin exerted its regulatory role by negative feedback on ALA synthase in the presence of SA and Epo. Heme potentiated Epo action and resulted in the increase of human marrow erythroid progenitor cell proliferation and differentiation and a concomitant stimulation of ALA synthase and PBG deaminase. The potentiating effects of hemin on CFU-E growth were observed in human bone marrow cells cultured in media supplemented with fetal calf serum or serum-free media with interleukin 3 (IL-3). These results indicate that Epo is a potent inducer of ALA synthase and PBG deaminase in normal human bone marrow. In addition, our results may explain the mechanisms by which heme potentiates Epo or IL-3 enhancement of erythropoiesis. 1) Heme may stimulate the translation of several globin and nonglobin mRNAs, including those of ALA synthase and PBG deaminase; 2) as endogenous cellular heme synthesis reaches optimal levels, heme exerts its regulatory role on ALA synthase by negative feedback inhibition. Additionally, an increase in cellular heme may lead to an increase in its own degradation by induction of heme oxygenase.
Department of Medicine, New York Medical College, Valhalla 10595.
N G
NG
Abraham
J C
JC
Nelson
T
T
Ahmed
G
G
Konwalinka
R D
RD
Levere
D000624:5-Aminolevulinate Synthetase / Q000378:metabolism; D001853:Bone Marrow / Q000201:enzymology*; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D004357:Drug Synergism; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects; D004921:Erythropoietin / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D006418:Heme / Q000378:metabolism*; D006419:Heme Oxygenase (Decyclizing) / Q000378:metabolism; D006427:Hemin / Q000494:pharmacology; D006537:Heptanoates / Q000494:pharmacology; D006801:Humans; D011163:Hydroxymethylbilane Synthase / Q000378:metabolism; D009994:Osmolar Concentration; D012016:Reference Values
D006537:Heptanoates; D004921:Erythropoietin; D006418:Heme; C020804:succinylacetone; D006427:Hemin; D006419:Heme Oxygenase (Decyclizing); D000624:5-Aminolevulinate Synthetase; D011163:Hydroxymethylbilane Synthase